

available on the web
www.prous.com/journals

Volume 27, Number 10, October 2002

Drugs of the Future

THE OHIO STATE UNIVERSITY LIBRARIES
Received on: 02-25-03
BPL-Bio Sci/Pharm Lib.
RM1D84
C.1



PROUS SCIENCE

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

Drugs of the Future

Editor: J.R. Prous

Chemical Editorial Staff: J. Castañer, R.M. Castañer, M. del Fresno, L. Martín, J. Prous

Editorial Staff: M. Bayés, M. Cullell-Young, P. Leeson, N.E. Mealy, X. Rabasseda, L. Revel, J. Silvestre, L.A. Sorbera

Contributing Editors:

M. Abou-Gharbia (USA), S.K. Ahn (S. Korea), L. de Angelis (Italy), E. de Clercq (Belgium), G. Eastland (USA), J. Engel (Germany), R.A. Fromling (USA), J. García-Rafanell (Spain), R.G. Glushkov (Russia), L. Hansson (Sweden), S.J. Hopkins (UK), A. Hoshi (Japan), J. Kim (S. Korea), H. Koch (Austria), P. Kocis (USA), S.K. Kulkarni (India), G. Leclerc (France), M. Levin (USA), W. Löscher (Germany), R. Mannhold (Germany), M. Neuman (France), M. Nikolova (Bulgaria), M. Nógrádi (Hungary), R. Panchagnula (India), J.T. Pento (USA), S. Rádl (Czech Rep.), J. Ruyun (China), F. Uckun (USA), J.T. Xie (China), R.K.-Y. Zee-Cheng (USA)

Drugs of the Future is a monthly publication designed to provide in monograph form information on new drugs from their first phases of development up to their marketing.

An information Update section appears monthly providing the most recent information available on drugs whose monographs were published in the same-numbered issue of previous volumes. Drug information in this section can be consulted by developmental phase or alphabetical order.

Articles on topical fields, presented by leading specialists, explore the innovative areas of drug research and highlight the mechanisms by which drugs act, relating chemical structures to specific biological activities.

Monographs

- 923 Erlotinib Hydrochloride. *Oncolytic, EGF receptor inhibitor*. L.A. Sorbera, J. Castañer, J.S. Silvestre, M. Bayés
935 Minodronic Acid. *Treatment of osteoporosis, Treatment of bone metastasis, Treatment of multiple myeloma*.
L.A. Sorbera, J. Castañer, P.A. Leeson
942 Pipendoxifene. *Treatment of breast cancer, Estrogen receptor modulator*. L.A. Sorbera, J. Castañer, J.S. Silvestre

Review Articles

- 949 Biological activities of resveratrol and its analogs
F. Wolter, J. Stein
961 Carrier systems for the treatment of inflammatory bowel disease
A. Lamprecht, A. Stallmach, Y. Kawashima, C.-M. Lehr
973 Present and future pharmacotherapy for benign prostatic hyperplasia
S.A. Doggrell
987 Small-molecule glucagon receptor antagonists
A. Ling

Annual Review: Psychopharmacologic Drugs

- | | | | |
|------|--------------------------|------|----------------------------|
| 998 | Aripiprazole | 1010 | Lamotrigine |
| 1001 | Blonanserin | 1013 | Lesopitron Dihydrochloride |
| 1002 | Deramciclone Fumarate | 1014 | MDL-100907 |
| 1002 | Duloxetine Hydrochloride | 1014 | Nemifitide Ditriflutate |
| 1005 | E-5842 | 1015 | Org-5222 |
| 1005 | Escitalopram Oxalate | 1016 | Pagoclone |
| 1007 | Gepirone Hydrochloride | 1016 | Perospirone Hydrochloride |
| 1008 | Iloperidone | 1017 | Pregabalin |
| | | 1018 | Vilazodone Hydrochloride |
| | | 1019 | Spotlights |

Psychopharmacologic Drugs

*N.E. Mealy, R. Castañer, L. Martín, M. del Fresno, L. Revel, M. Bayés, M. Stringer,
L.A. Sorbera, P. Cole, M. Cullell-Young, P.A. Leeson, J. Prous*

Abstract

This month's *Annual Review* is dedicated to updated information on psychopharmacologic drugs. The following table lists 86 drugs under development in this area, some of which have been published in previous issues of the journal and others that have been marketed for an indication other than that discussed in the review. Information on the following 17 products is updated here: **aripiprazole, blonanserin, deramciclone fumarate, duloxetine hydrochloride, E-5842, escitalopram oxalate, gepirone hydrochloride, iloperidone, lamotrigine, lesopitron dihydrochloride, MDL-100907, nemifitide ditriflutate, Org-5222, pagoclone, perospirone hydrochloride, pregabalin and vilazodone hydrochloride.** A new addition to the *Annual Review* series, entitled Spotlights, begins this month and provides profiles of drugs which have not been previously published in the journal but are under active development in the area under review. Drugs featured in the Spotlights section this month are: **abaperidone hydrochloride, ACR-16, agomelatine, ANPH-101, ANPH-102, aprepitant, AR-A2, AVE-5997, bifeprunox, cannabidiol, CEE-310, CP-122721, CX-516, DOV-216303, DU-125530, E-6039, elzasonan hydrochloride, EMR-62218, eplivanserin, eszopiclone, gaboxadol, GW-353162, GW-597599, indiplon, itriglumide, levetiracetam, LU-36,138, LY-156735, LY-354740, melatonin, NBI-34041, NE-100, NGD-96-3, ocinaplon, olanzapine/fluoxetine, OPC-14523, Org-24448, Org-34167, Org-34517, osanetant, R-673, R-1204, saredutant, SB-271046, SB-723620, secretin (synthetic human), SEP-174559, sertindole, (*R*)-sibutramine metabolite, SL-65.1498, SLV-308, SLV-310, SLV-313, SLV-314, SLV-319, SM-13496, SNEC-2, sodium oxybate, SR-58611, SR-144190, TAK-375, talnetant and valproic acid sodium salt.**

We remind our readers that the Prous Science **Integrity** database provides continuously updated information on the products covered in this *Annual Review*.

This material may be protected by Copyright law (Title 17 U.S. Code)

Annual Review 2002: Psychopharmacologic Drugs

| Drug | Source | Indication/Action | Phase |
|---|---|------------------------------|----------|
| Abaperidone Hydrochloride | Ferrer | Antipsychotic | I |
| ACR-16 | Carlsson Research | Antipsychotic | I |
| Agomelatine | Servier | Antidepressant | III |
| ANPH-101 | Ancile | Sleep disorders | II/III |
| ANPH-102 | Ancile | Anxiolytic | II |
| Aprepitant ¹ | Merck & Co. | Antidepressant | III |
| AR-A2 | AstraZeneca | Antidepressant | I |
| Aripiprazole¹ | Otsuka/Bristol-Myers Squibb | Antipsychotic | R-2002 |
| | | Bipolar disorder | III |
| AVE-5997 | Aventis Pharma | Antipsychotic | I |
| Bifeprunox | Solvay/Lundbeck | Antipsychotic | II |
| Blonanserin¹ | Dainippon Pharmaceutical | Antipsychotic | III |
| Cannabidiol | GW Pharmaceuticals | Antipsychotic | I |
| CEE-310 | CeNeS | Sleep disorders | II |
| CP-122721 | Pfizer | Antidepressant | II |
| CX-516 | Cortex/Organon | Antipsychotic | II |
| | Rush Presbyterian-St. Luke's Med. Center | Autism | II |
| Deramciclane Fumarate¹ | Orion Corp./Pharmacia | Generalized anxiety disorder | III |
| DOV-216303 | DOV Pharmaceutical | Antidepressant | I |
| DU-125530 | Solvay | Antidepressant | II |
| Duloxetine Hydrochloride¹ | Lilly/Shionogi | Antidepressant | Prereg |
| E-5842¹ | Esteve | Antipsychotic | II |
| E-6039 | Esteve | Antidepressant | I |
| Elzasonan Hydrochloride | Pfizer | Antidepressant | II |
| EMR-62218 | Merck KGaA | Antipsychotic | I |
| Eplivanserin | Sanofi-Synthelabo | Antipsychotic | II |
| Escitalopram Oxalate¹ | Lundbeck/Forest | Antidepressant | L-2002 |
| | Lundbeck/Forest | Panic disorder | L-2002 |
| | Lundbeck | Social anxiety disorder | III |
| Eszopiclone | Sepracor | Sedative/Hypnotic | III |
| Gaboxadol | Lundbeck | Sleep disorders | II/III |
| Gepirone Hydrochloride¹ | Organon | Antidepressant | Prereg |
| GW-353162 | GlaxoSmithKline | Antidepressant | I |
| | | Bipolar disorder | I |
| GW-597599 | GlaxoSmithKline | Antidepressant | II |
| | | Anxiolytic | II |
| Iloperidone¹ | Novartis/Titan | Antipsychotic | III |
| Indiplon | DOV Pharmaceutical/Neurocrine Biosciences | Sleep disorders | III |
| Itriglumide ¹ | Rotta | Anxiolytic | I |
| Lamotrigine^{1,2} | GlaxoSmithKline | Bipolar disorder | III |
| Lesopitron Dihydrochloride¹ | Esteve | Generalized anxiety disorder | II |
| Levetiracetam ^{1,2} | UCB | Bipolar disorder | Clinical |
| LU-35-138 | Lundbeck | Antipsychotic | I |
| LY-156735 | Lilly/Phase 2 Discovery | Sedative/Hypnotic | I |
| LY-354740 | Lilly | Anxiolytic | I |
| MDL-100907¹ | Aventis Pharma | Sleep disorders | I |
| Melatonin | Paladin/Neurim | Sleep disorders | Prereg |
| NBI-34041 | Neurocrine Biosciences | Antidepressant | I |
| | Neurocrine Biosciences/GlaxoSmithKline | Anxiolytic | I |
| NE-100 | Taisho | Antipsychotic | II |
| Nemifitide Ditriflutate¹ | Innapharma | Antidepressant | II/III |
| NGD-96-3 | Neurogen/Pfizer | Sleep disorders | I |
| Ocinaplon | DOV Pharmaceutical/Elan | Generalized anxiety disorder | II |
| Olanzapine/Fluoxetine | Lilly | Antidepressant | III |
| OPC-14523 | Otsuka | Antidepressant | II |
| Org-24448 | Cortex/Organon | Antipsychotic | II |
| Org-34167 | Organon | Antidepressant | II |
| Org-34517 | Organon | Antidepressant | II |
| Org-5222¹ | Organon | Antipsychotic | III |
| Osanetant | Sanofi-Synthelabo | Antidepressant | II |
| | | Antipsychotic | II |

Continued

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.